Open an account

Cerus

CERS · NASDAQ

$2.31+$0.09 (+4.05%)TodayMarket closed ·
Prev close $2.22

About CERS

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 275 full-time employees. The firm is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.

Employees
275
Headquarters
Concord, California
Listed
Jan 31, 1997
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
cerus.com

CERS key statistics

Market cap
465.52M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.95M
Volume
1.48M
Open price
$2.25
High today
$2.31
Low today
$2.23
52 Week high
$3.47
52 Week low
$1.38

Cerus (CERS) at a glance

Cerus (CERS) last traded at $2.31, with a market cap of 465.52M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.23 and $2.31. The current price is 3.6% above the day's low and 0.0% below its high.

Volume so far is 1.48M shares, below the average of 1.95M shares a day.

Over the past year Cerus has ranged from $1.38 to $3.47, and now sits 45% of the way up that range.

Cerus met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.01 per share against an estimate of -$0.0136.

The average analyst price target is $5.23, 126.3% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $5.23
Low
$4.04
Now
$2.31
High
$6.82

CERS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 47.8% on average.

  1. Q3 FY24: reported -$0.02 per share against an estimate of -$0.0306
  2. Q4 FY24: reported -$0.01 per share against an estimate of -$0.0119
  3. Q1 FY25: reported -$0.04 per share against an estimate of -$0.0428
  4. Q2 FY25: reported -$0.03 per share against an estimate of -$0.0281
  5. Q3 FY25: reported $0.00 per share against an estimate of -$0.0281
  6. Q4 FY25: reported -$0.01 per share against an estimate of -$0.0408
  7. Q1 FY26: reported -$0.01 per share against an estimate of -$0.0408
  8. Q2 FY26: reported -$0.01 per share against an estimate of -$0.0136

CERS news

  • Press releaseBusiness Wire

    Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026

  • Press releaseBusiness Wire

    Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Press releaseBusiness Wire

    Cerus Corporation Announces Second Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026

  • Press releaseBusiness Wire

    Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress

  • Shivdeep Dhaliwal

    Cathie Wood Sells Robinhood Stock, Doubles Down On This George Soros-Backed AI Stock

  • Press releaseBusiness Wire

    Cerus Corporation Closes New Debt Facility of Up to $110 Million

Similar companies

Companies in the same industry as Cerus

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.